{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:29:13Z","timestamp":1788218953927,"version":"build-2803163510"},"reference-count":40,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15247","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:22:02Z","timestamp":1756293722000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non\u2011small cell lung cancer"],"prefix":"10.3892","volume":"30","author":[{"given":"Wenyi","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghui","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The First Affiliated Hospital of Shaoyang University, Shaoyang, Hunan 422000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan 410013, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"key20251007110246_b1-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.athoracsur.2021.06.069","article-title":"Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer","volume":"114","author":"Lee","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"key20251007110246_b2-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cac2.12153","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art","volume":"41","author":"Kang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"key20251007110246_b3-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.lungcan.2020.07.001","article-title":"Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis","volume":"147","author":"Jia","year":"2020","journal-title":"Lung Cancer"},{"key":"key20251007110246_b4-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann Surg"},{"key":"key20251007110246_b5-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"2085267","DOI":"10.1155\/2022\/2085267","article-title":"Neoadjuvant immunotherapy improves treatment for early resectable non-small-cell lung cancer: A systematic review and meta-analysis","volume":"2022","author":"Dong","year":"2022","journal-title":"J Oncol"},{"key":"key20251007110246_b6-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1286104","DOI":"10.3389\/fonc.2023.1286104","article-title":"Neoadjuvant therapy in non-small cell lung cancer: Basis, promise, and challenges","volume":"13","author":"Kalvapudi","year":"2023","journal-title":"Front Oncol"},{"key":"key20251007110246_b7-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"17588359231163798","DOI":"10.1177\/17588359231163798","article-title":"Neoadjuvant immunotherapy in resectable non-small-cell lung cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"key20251007110246_b8-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251007110246_b9-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"key20251007110246_b10-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers16071302","article-title":"An updated review of management of resectable stage III NSCLC in the era of neoadjuvant immunotherapy","volume":"16","author":"Verma","year":"2024","journal-title":"Cancers (Basel)"},{"key":"key20251007110246_b11-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"key20251007110246_b12-ol-30-5-15247","first-page":"145","article-title":"New TNM staging in lung cancer (8th edition) and future perspectives","volume":"6","author":"Matilla","year":"2020","journal-title":"J Clin Transl Res"},{"key":"key20251007110246_b13-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20251007110246_b14-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20251007110246_b15-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"key20251007110246_b16-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5306\/wjco.v13.i9.758","article-title":"Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy","volume":"13","author":"Aguado","year":"2022","journal-title":"World J Clin Oncol"},{"key":"key20251007110246_b17-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3390\/jcm13092715","article-title":"Revolutionizing localized lung cancer treatment: Neoadjuvant chemotherapy plus immunotherapy for all?","volume":"13","author":"Ferrari","year":"2024","journal-title":"J Clin Med"},{"key":"key20251007110246_b18-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"119S","DOI":"10.1378\/chest.117.4_suppl_1.119S","article-title":"Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: A time for reassessment?","volume":"117","author":"Bunn","year":"2000","journal-title":"Chest"},{"key":"key20251007110246_b19-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"758","DOI":"10.5306\/wjco.v13.i9.758","article-title":"Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing-and fast","volume":"13","author":"Aguado","year":"2022","journal-title":"World J Clin Oncol"},{"key":"key20251007110246_b20-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/cancers16010156","article-title":"The efficacy and safety of neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"16","author":"Guven","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20251007110246_b21-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"key20251007110246_b22-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-Year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"key20251007110246_b23-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"102040","DOI":"10.1016\/j.esmoop.2023.102040","article-title":"Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: Subpopulation analysis of Chinese patients in CheckMate 816","volume":"8","author":"Wang","year":"2023","journal-title":"ESMO Open"},{"key":"key20251007110246_b24-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1479263","DOI":"10.3389\/fimmu.2024.1479263","article-title":"Efficacy and safety of neoadjuvant chemoimmunotherapy and chemotherapy in patients with potentially resectable stage IIIA\/IIIB NSCLC: A retrospective study","volume":"15","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"key20251007110246_b25-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): An interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"key20251007110246_b26-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"key20251007110246_b27-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.jtcvs.2010.02.039","article-title":"Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer","volume":"139","author":"Weder","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20251007110246_b28-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.21037\/jtd.2017.10.92","article-title":"Pneumonectomy is safe and effective for non-small cell lung cancer following induction therapy","volume":"9","author":"White","year":"2017","journal-title":"J Thorac Dis"},{"key":"key20251007110246_b29-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.21037\/jtd.2020.02.33","article-title":"The analysis of prognosis factor in patients with non-small cell lung cancer receiving pneumonectomy","volume":"12","author":"Wang","year":"2020","journal-title":"J Thorac Dis"},{"key":"key20251007110246_b30-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2008-1038985","article-title":"Prospective study on perioperative risks and functional results in bronchial and bronchovascular sleeve resections","volume":"57","author":"Schirren","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"key20251007110246_b31-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"S872","DOI":"10.21037\/jtd.2016.06.48","article-title":"Bronchial and arterial sleeve resection for centrally-located lung cancers","volume":"8","author":"Maurizi","year":"2016","journal-title":"J Thorac Dis"},{"key":"key20251007110246_b32-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.21037\/jtd-22-654","article-title":"Analyzing the impact of minimally invasive surgical approaches on post-operative outcomes of pneumonectomy and sleeve lobectomy patients","volume":"15","author":"Nitsche","year":"2023","journal-title":"J Thorac Dis"},{"key":"key20251007110246_b33-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1378\/chest.09-2547","article-title":"Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: A review of SEER data","volume":"139","author":"Kates","year":"2011","journal-title":"Chest"},{"key":"key20251007110246_b34-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1245\/s10434-021-10857-7","article-title":"Comparison between wedge resection and lobectomy\/segmentectomy for early-stage non-small cell lung cancer: A bayesian meta-analysis and systematic review","volume":"29","author":"Shi","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"key20251007110246_b35-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.21037\/tlcr.2019.03.12","article-title":"Tobacco and the lung cancer epidemic in China","volume":"8","author":"Parascandola","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"key20251007110246_b36-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"684070","DOI":"10.3389\/fonc.2021.684070","article-title":"Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"key20251007110246_b37-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ejcts\/ezab007","article-title":"Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer","volume":"60","author":"Romero Rom\u00e1n","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"key":"key20251007110246_b38-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"938269","DOI":"10.3389\/fimmu.2022.938269","article-title":"An open, observational, three-arm clinical study of 2\u20133 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis","volume":"13","author":"Gu","year":"2022","journal-title":"Front Immunol"},{"key":"key20251007110246_b39-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: The TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20251007110246_b40-ol-30-5-15247","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2021.09.010","article-title":"Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: The AEGEAN trial","volume":"23","author":"Heymach","year":"2022","journal-title":"Clin Lung Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:03:33Z","timestamp":1759824213000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,8,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15247","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}